Atomera Incorporated vs Stryker Corporation — how do they compare? Atomera Incorporated trades at $5.57 (market cap $209.56M), while Stryker Corporation trades at $347.43 (market cap $132.64B). The key difference: Stryker Corporation is far larger — about 632.9× Atomera Incorporated's market cap, and Stryker Corporation pays a 1.02% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ATOM | SYK | |
|---|---|---|
Market Cap | $209.56M | $132.64B |
Sector | Technology | Technology |
52-Week High | $12.11 | $394.34 |
52-Week Low | $1.99 | $282.58 |
Enterprise Value | $172.37M | $144.11B |
Dividend Yield | — | 1.02% |
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.
Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.
Stryker (SYK) trades at $339.03, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $3.69 versus $3.49 expected, and demonstrated robust 9% organic sales growth. Analyst consensus is strongly positive with a $379.44 price target and 74% buy ratings. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS robotic technology.
The outlook remains favorable given earnings momentum and product innovation, though risks include competitive pressures and potential cyber disruptions. Valuation multiples such as a P/E of 35.84 suggest premium pricing, requiring sustained growth to justify. Institutional ownership trends show mixed activity, with some funds increasing stakes recently.
Trailing returns across standard periods
Latest headlines on both assets
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →